Telix (ASX:TLX) Pixclara NDA Resubmitted, The FDA Clock Restarts

Pixclara Back With the FDA

Telix has resubmitted its NDA to the FDA for Pixclala, its PET imaging agent for recurrent or progressive glioma, a common type of brain tumour.

Pixclara is a targeted amino acid PET scan designed to help distinguish true tumour recurrence from treatment-related changes in adult patients. That is a real clinical problem because after surgery and treatment, a standard MRI often cannot reliably tell whether a new lesion is returning cancer or tissue damage caused by treatment. Getting that wrong can have major consequences for how patients are managed.

The original NDA was rejected on 28 April 2025 through a complete response letter, meaning the FDA was not satisfied with the first submission.

What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips

Why did Telix originally get rejected?

The likely issue was the FDA wanting more detailed evidence around diagnostic accuracy across different patient subgroups, including adult versus paediatric patients, tumour grades, and specific glioma subtypes. Given Pixclara is being positioned for both adult and paediatric indications, that was likely a key point of scrutiny.

The FDA may also have wanted clearer head-to-head data versus standard MRI, or more clarity around how histopathology, meaning surgical biopsy, was used as the reference standard for the primary endpoint. Telix appears to have gone back through its clinical database, completed the additional analyses requested by the FDA, and repackaged the submission.

Why did it take 10 months to resubmit?

On 28 April, the FDA stated that additional efficacy data and supporting evidence were required for the application to progress. This was despite Telix having gone through a robust consultation process with the FDA beforehand. Importantly, the FDA did not raise any safety concerns. The issue was more about needing greater clarity on the clinical value of Pixclara and how it could improve patient outcomes.

Then in September 2025, Telix reached an agreement with the FDA on the path forward. The company announced that the resubmission package would include an additional confirmatory efficacy study based on existing data. In other words, Telix did not need to run a brand new clinical trial, but it did need to go back into its clinical database, design a new study analysis, and generate the extra evidence the FDA wanted.

That is the key reason the resubmission took time. Telix essentially had to rework the data it already had into a new confirmatory study format that better addressed the FDA’s concerns.

Fiscal year guidance will remain unchanged

For investors, this does not change FY26 guidance because management’s targets are based only on currently approved FDA products. Any Pixclara approval would be incremental revenue, likely from H2 FY26 at the earliest given Fast Track review timelines.

Why is this more important than the market thinks?

The bigger strategic point is that Pixclara uses the same LAT1 and LAT2 target as TLX101-Tx, Telix’s GBM therapy candidate. In simple terms, that creates strong synergies between the imaging agent and the therapy. Pixclara could be used to identify patients with brain tumours, and those same patients could then move into treatment with Telix’s therapy. That is why a Pixclara approval would strengthen the broader GBM franchise.

Telix has already had a Type A meeting, received specific guidance on the additional analysis required, and believes it has addressed the complete response letter. The resubmission clock now restarts, and with Fast Track status the FDA action date could come within six months, potentially sooner. If approved, Pixclara would be pure upside to current numbers and would meaningfully de-risk the broader GBM franchise ahead of the IPAX-BrIGHT readout.